An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Namacizumab (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; First in man
- Sponsors Bird Rock Bio
- 05 Jun 2017 According to a Bird Rock Bio media release, the company has completed the single ascending dose portion of the trial.
- 10 Feb 2017 Planned initiation date changed from 31 Jan 2017 to 14 Feb 2017.
- 10 Feb 2017 Status changed from not yet recruiting to recruiting.